NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
Clinical Trials
19 trialsNCT06024941 2024-09-19
Re-Induce 2
Maastricht Radiation Oncology
Phase 2 Withdrawn
NCT05929716 2023-11-13
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05161533 2023-10-18
Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
University of Washington
Phase 2 Withdrawn
NCT04989283 2023-09-26
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT02716688 2023-09-22
S-1 and Radiotherapy for Elderly Esophageal Cancer Patients
Zhejiang Provincial People's Hospital
Phase 2 Withdrawn
NCT03982537 2022-12-19
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT03834571 2022-06-21
Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women
AIDS Malignancy Consortium
Phase 2 Withdrawn
NCT04585932 2021-01-20
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03506139 2020-09-09
Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma
University of Iowa
Phase 2 Withdrawn
NCT00934518 2019-02-12
Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
Milton S. Hershey Medical Center
Phase 2 Withdrawn
NCT03419130 2018-12-07
Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT02962804 2018-03-05
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
University of Kansas Medical Center
Phase 2 Withdrawn
NCT00984217 2016-01-08
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
University of Pittsburgh
Phase 2 Withdrawn
NCT02599090 2015-11-06
Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02120118 2015-06-09
Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors
Shin Kong Wu Ho-Su Memorial Hospital
Phase 2 Withdrawn
NCT01130701 2015-03-17
PMABIIS
University of Massachusetts, Worcester
Phase 2 Withdrawn
NCT00346099 2008-01-07
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum
NSABP Foundation Inc
Phase 2 Withdrawn